# ZYNRELEF

Type: Product

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/zynrelef
Canonical HTML page: https://getfinancebrief.com/entity/zynrelef

## Recent coverage (1 stories)

### Mid-Cap Biotech Resilience: Lantheus and Heron Navigate Mixed Q4 Results
2026-02-26 13:18:52 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter results for 2025, characterized by revenue growth offset by margin pressures. Crucially, both firms took the rare step of introducing fiscal year 2026 guidance, signaling a strategic shift toward long-term stability in the radiopharmaceutical and acute care markets.
Full story: https://getfinancebrief.com/story/lantheus-heron-q4-earnings-fy26-outlook

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.